LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Suletud

1.22 -2.4

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.22

Max

1.29

Põhinäitajad
By Trading Economics
Sissetulek	17M -26M
Aktsiakasum	-0.43
Kasumimarginaal	-2,190.837
Töötajad	171
EBITDA	19M -23M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+140% upside

Turustatistika
By TradingEconomics
Turukapital	-26M 76M
Eelmine avamishind	3.62
Eelmine sulgemishind	1.22

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. dets 2025, 23:50 UTC

Kuumad aktsiad

Stocks to Watch: Micron, MillerKnoll, HireQuest, Insmed

17. dets 2025, 23:20 UTC

Tulu

Correction to Micron Logs Sales Jump Article

17. dets 2025, 23:07 UTC

Tulu

Micron Logs Sales Jump, Sees Further Growth as AI Demand Outpaces Supply -- Update

17. dets 2025, 21:37 UTC

Tulu

Micron Technology 1Q Sales Jump 57%, Led By Memory Growth

17. dets 2025, 23:53 UTC

Market Talk

Gold Edges Higher, Supported by Some Tailwinds -- Market Talk

17. dets 2025, 23:43 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

17. dets 2025, 23:06 UTC

Omandamised, ülevõtmised, äriostud

Asahi Group: Transaction Expected to Be Closed in 2H of Calendar Year 2026

17. dets 2025, 23:05 UTC

Omandamised, ülevõtmised, äriostud

Asahi Group: Currently No Plans of Issuing New Shares in Asahi

17. dets 2025, 23:04 UTC

Omandamised, ülevõtmised, äriostud

Asahi Group: Funds to Be Provided Via Borrowings From Financial Institutions or Cash on Hand

17. dets 2025, 23:03 UTC

Omandamised, ülevõtmised, äriostud

Asahi Group: Acquisition of 53.68% Stake in UDV (Kenya) is $646M on Equity Value Basis

17. dets 2025, 23:02 UTC

Omandamised, ülevõtmised, äriostud

Asahi Group: Acquisition of 100% Stake in Diageo Kenya is $2.354B on Equity Value Basis

17. dets 2025, 22:59 UTC

Omandamised, ülevõtmised, äriostud

Asahi Group: Deal Part of Strategy Under Medium- to Long-Term Management Policy

17. dets 2025, 22:57 UTC

Omandamised, ülevõtmised, äriostud

Asahi Group: To Indirectly Acquire 65.00% Stake in East African Breweries PLC

17. dets 2025, 22:56 UTC

Omandamised, ülevõtmised, äriostud

Asahi Group: Stakes Acquired From Two Subsidiaries of Diageo Plc

17. dets 2025, 22:55 UTC

Omandamised, ülevõtmised, äriostud

Asahi Group Holdings: To Acquire 100% Stake in Diageo Kenya Ltd., 53.68% Stake in UVD (Kenya) Ltd.

17. dets 2025, 22:49 UTC

Market Talk

Sandfire Resources Production Pipeline Strength Questioned -- Market Talk

17. dets 2025, 21:58 UTC

Tulu

Micron Crushes Earnings. The Stock Is Rising. -- Barrons.com

17. dets 2025, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

17. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. dets 2025, 21:46 UTC

Tulu

Salesforce and Other AI Stocks That Can Catch Up to the Pack -- Barrons.com

17. dets 2025, 21:20 UTC

Tulu

Micron Crushes Earnings. The Stock Is Rising. -- Barrons.com

17. dets 2025, 21:10 UTC

Tulu

Micron Beats Earnings. The Stock Is Rising. -- Barrons.com

17. dets 2025, 21:05 UTC

Tulu

Micron Technology Anticipates Business Performance to Continue Strengthening Through FY26

17. dets 2025, 21:04 UTC

Tulu

Micron Technology: 2Q Outlook Reflects Substantial Records Across Rev, Gross Margin, EPS and Free Cash Flow >MU

17. dets 2025, 21:04 UTC

Tulu

Micron Technology Sees 2Q Oper Expenses $1.56B, Plus or Minus $20M >MU

17. dets 2025, 21:03 UTC

Tulu

Micron Technology Sees 2Q Adj EPS $8.42, Plus or Minus 20c >MU

17. dets 2025, 21:03 UTC

Tulu

Micron Technology Sees 2Q EPS $8.19, Plus or Minus 20c >MU

17. dets 2025, 21:03 UTC

Tulu

Micron Technology Sees 2Q Revenue $18.7B, Plus or Minus $400M >MU

17. dets 2025, 21:02 UTC

Tulu

Micron Technology 1Q Operating Cash Flow $8.41 B >MU

17. dets 2025, 21:01 UTC

Tulu

Micron Technology 1Q Rev $13.64B >MU

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

140% tõus

12 kuu keskmine prognoos

Keskmine 3 USD 140%

Kõrge 4 USD

Madal 2 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.